Douglas Thorburn

机构：Royal Free London NHS Foundation Trust · ORCID：0000-0002-5610-5448

发表论文 412 篇 · 总被引 11569 次 · h-index 58

代表论文

• Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD (2025 · Journal of Hepatology · 被引 30)
• Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial (2025 · Journal of Hepatology · 被引 23)
• Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis (2025 · Journal of Hepatology · 被引 14)
• Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 11)
• Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis (2025 · Alimentary Pharmacology & Therapeutics · 被引 7)
• OS-089 Elafibranor for primary sclerosing cholangitis: the ELMWOOD phase II randomised controlled trial (2025 · Journal of Hepatology · 被引 4)